Business Context and Reporting Period
Company: Altimmune, Inc. (Nasdaq: ALT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Altimmune is a late clinical-stage biopharmaceutical company developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide, is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company has not yet generated revenue from product sales.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenues | $0.04 million | $0.02 million |
| Net Loss | $(88.1) million | $(95.1) million |
| Operating Expenses | $94.5 million | $103.2 million |
| Research & Development (R&D) | $66.4 million | $82.2 million |
| General & Administrative (G&A) | $28.1 million | $21.0 million |
| Cash, Cash Equivalents, and Short-Term Investments | $273.5 million | $131.9 million |
| Accumulated Deficit | $(649.5) million | $(561.4) million |
| Debt (Term Loan Principal) | $35.0 million | $0 |
Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product revenue.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $7.0 million (7%) compared to 2024, primarily driven by a reduction in R&D expenses.
- R&D Expense Decline: R&D expenses decreased by $15.8 million (19%). This was largely due to the completion of the IMPACT Phase 2b trial enrollment in early 2025 and the winding down of nonclinical activities, partially offset by the initiation of new trials for AUD and ALD.
- G&A Expense Increase: G&A expenses increased by $7.1 million (34%), driven by higher professional services fees and stock-based compensation, including $1.4 million in severance costs for former executives.
- Debt Financing: The company entered into a Term Loan agreement in May 2025, drawing $35.0 million in principal by year-end, resulting in $1.6 million of interest expense for the year.
- Liquidity Improvement: Cash and short-term investments more than doubled to $273.5 million, supported by $173.3 million in net proceeds from at-the-market equity offerings and $33.9 million from the Term Loan.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Phase 3 Preparation: Following positive 48-week data from the IMPACT Phase 2b MASH trial and an End-of-Phase 2 meeting with the FDA in December 2025, the company is preparing to initiate a pivotal Phase 3 trial in MASH in 2026. The FDA agreed to the use of an AI pathology tool (AIM-MASH AI Assist) for the trial.
- Additional Indications: Enrollment was completed ahead of schedule for the RECLAIM Phase 2 trial in AUD (results expected in 2026). The RESTORE Phase 2 trial in ALD is ongoing.
- Capital Resources: Management believes current cash resources are sufficient to fund operations for at least the next twelve months. However, the company expects to require additional capital to complete clinical trials and commercialize products.
Risks and Contingencies
- Profitability: The company has incurred significant losses since inception and anticipates continuing to incur losses for the foreseeable future. It has no approved products and no assurance of future revenue.
- Regulatory Approval: Success depends on obtaining regulatory approval for pemvidutide. Clinical trials may fail, or regulatory authorities may require additional studies.
- Debt Covenants: The Term Loan includes restrictive covenants and an event of default could require immediate repayment, potentially forcing the company to delay or terminate development programs.
- Intellectual Property: The company relies on in-licensed patents from Mederis Diabetes, LLC. Failure to maintain these rights or defend against infringement claims could harm the business.
- Legal Proceedings: A securities class action and a shareholder derivative action filed in 2025 were voluntarily dismissed without prejudice in late 2025.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $273.5 million cash balance against the projected costs of the upcoming Phase 3 MASH trial and ongoing Phase 2 trials in AUD and ALD.
- Debt Terms: Review the specific milestones required to draw the remaining $90 million available under the amended Term Loan and the impact of the 9.70%+ interest rate and end-of-term charges on future cash flow.
- Phase 3 Timeline: Confirm the initiation date and enrollment targets for the pivotal Phase 3 MASH trial scheduled for 2026.
- Patent Expiry: Assess the expiration dates of the in-licensed patents (extending into the 2040s) and the robustness of the IP portfolio against potential challenges.
- Regulatory Feedback: Review the final minutes from the December 2025 End-of-Phase 2 FDA meeting to ensure alignment on Phase 3 endpoints and the use of AI pathology tools.